Supplements vergleichen

Off-label (male) / approved (female) — clinician-directed. For female ovulation induction the approved regimen is 50 mg once daily for 5 days starting early in the cycle, titrated up to 100-150 mg if needed. For off-label male hypogonadism, observational studies used roughly 25-50 mg daily or every other day (25 mg/day is the most common starting dose), titrated to testosterone and LH/FSH response. There is no FDA-approved male dose.

Any time

Clomifencitrat-Tabletten (razemisch — zugelassen für Frauen; off-label bei Männern)

Investigational / off-label — no FDA-approved dose exists. Trials studied oral enclomiphene citrate at 6.25-25 mg once daily (12.5 mg and 25 mg were the Phase-3 doses). Compounded enclomiphene is used off-label under a clinician at similar doses, but quality and content are not regulated.

Any time

Orales Enclomiphencitrat (als Rezeptur hergestellt; in Erprobung — nie als zugelassenes Arzneimittel vermarktet)

• Pregnancy (clomiphene is contraindicated once pregnancy is established)
• Liver disease, undiagnosed abnormal uterine bleeding, or ovarian cysts not due to PCOS (per the approved female label)
• Primary (testicular) hypogonadism in men — needs an intact pituitary/testis axis to work

• Exogenous testosterone / anabolic steroids
• Aromatase inhibitors / other SERMs (e.g. tamoxifen, letrozole)
• Estrogens

• Primary (testicular) hypogonadism — needs an intact pituitary/testis axis to work
• Hormone-sensitive tumors or conditions worsened by raising testosterone/estrogen
• History of venous thromboembolism (class concern for SERMs)

• Exogenous testosterone / anabolic steroids
• Aromatase inhibitors / other SERMs (e.g. tamoxifen)
• Estrogens